Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House.
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House.
AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that's become a go-to place for drug R&D and industry dealmaking in the past year.
Sanofi CEO Paul Hudson emphasized the company’s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon an mRNA-based flu vaccine program.
An FDA rejection letter for Corcept Therapeutics’ potential hormonal disorder drug says the agency told the company it had serious concerns before the application was submitted.
Bitterroot Bio, a biotech from leading minds in the CD47 field, appears to have returned to the discovery stage after attempting to expand the potential of the "don't eat me" signal from the cancer field ...
Last week, the House Judiciary Committee came out with a report about CVS Health’s alleged antitrust behavior toward disruptive pharmacy models that provide digital services to other pharmacies. It details ...
Two companies that run on-site health clinics for employers like Google and Amazon are merging as healthcare costs continue to climb.
Ultragenyx has resubmitted its approval request for a rare disease gene therapy after the FDA rejected it last summer.
Eli Lilly has budgeted $3.5 billion for a new weight loss injectable and device factory in Lehigh Valley, PA, which will manufacture its next-gen obesity drug retatrutide.
Welcome back to Endpoints Weekly! Fourth-quarter earnings season is in full swing, and our team covered reports this week from Teva, Roche, Sanofi, Takeda and Regeneron. CMS also unveiled the next 15 drugs subject to ...
The leader in the next frontier of immuno-oncology officially has a date with the FDA.
→ William Go has replaced Zachariah McIver as CMO of Janux Therapeutics, a San Diego-based biotech that is partnering with Bristol Myers Squibb on a T cell engager ...
Amgen abruptly pulled out of a collaboration for a leading drug in its immunology pipeline on Friday, sending the asset back to its partner ahead of an FDA submission later this year.
With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Roche’s breast cancer drug giredestrant is sitting pretty.
Quince Therapeutics' once-monthly steroid-based treatment failed a Phase 3 trial for a rare genetic condition called ataxia-telangiectasia, prompting the Bay Area company to say it would stop development of the experimental ...